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Abstract 31 
The activation status of neutrophils can cycle from basal through primed to fully activated 32 
 ? ?green-amber-red'), and at least in vitro, primed cells can also spontaneously revert back to 33 
a near basal phenotype. This broad range of neutrophil responsiveness confers extensive 34 
functional flexibility, allowing these cells to respond rapidly and appropriately to varied and 35 
evolving threats throughout the body. Primed and activated cells display dramatically 36 
enhanced bactericidal capacity (including augmented respiratory burst activity, 37 
degranulation and longevity), but this enhancement also confers the capacity for significant 38 
unintended tissue injury. Neutrophil priming and its consequences have been associated 39 
with adverse outcomes in a range of disease states, hence understanding the signalling 40 
processes that regulate the transition between basal and primed states (and back again) 41 
may offer new opportunities for therapeutic intervention in pathological settings. A wide 42 
array of host- and pathogen-derived molecules have the capacity to modulate the functional 43 
status of these versatile cells. Reflecting this extensive repertoire of potential mediators, 44 
priming can be established by a range of signalling pathways (including mitogen-activated 45 
protein kinases, phosphoinositide 3-kinases, phospholipase D and calcium transients) and 46 
intracellular processes (including endocytosis, vesicle trafficking and the engagement of 47 
adhesion molecules). The signalling pathways engaged, and the exact cellular phenotype 48 
that results, vary according to the priming agent(s) to which the neutrophil is exposed and 49 
the precise environmental context. Herein we describe the signals that establish priming (in 50 
particular for enhanced respiratory burst, degranulation and prolonged lifespan) and 51 
describe the recently recognised process of de-priming, correlating in vitro observations with 52 
in vivo significance. 53 
 54 
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Introduction 55 
Circulating neutrophils are quiescent, and in health the vast majority undergo final disposal 56 
without encountering an activating signal. However, as first responders to infection or injury, 57 
neutrophils need the functional versatility to enable appropriate responses in the face of 58 
varied and evolving threats (Figure 1). Unprimed neutrophils exposed to activating agents 59 
such as fMLF, LTB4 or C5a secrete little or no granule contents or reactive oxygen species 60 
(ROS). However neutrophils that have been exposed to a range of agonists enter a state of 61 
high alert, with the capacity to respond aggressively (e.g. through degranulation, respiratory 62 
burst activity and increased lifespan) if a further activating stimulus is encountered. This pre-63 
activation or primed state was first recognised in vitro (1), and shortly afterwards shown to 64 
occur in vivo in the setting of systemic infection (2). A wide variety of priming agents 65 
(chemokines, cytokines, alarmins, integrins, pathogen-derived molecules and mechanical 66 
forces) have been identified, and primed neutrophils circulate in vivo in many inflammatory 67 
diseases (e.g. rheumatoid arthritis (3) and cystic fibrosis (4)) and pathological states (e.g. 68 
trauma or cardiopulmonary bypass (5, 6)). In keeping with the requirement for dynamic 69 
regulation of neutrophil activation (to ensure that maximal activation occurs only when and 70 
where required), primed cells also have the flexibility to spontaneously  ?ĚĞ-ƉƌŝŵĞ ?Žƌrevert 71 
back to the un-primed quiescent state (7); notably the retention of primed cells in vascular 72 
beds may even facilitate this de-escalation (8; Figure 1). Increased levels of circulating 73 
primed neutrophils correlate with adverse outcomes (6, 9), while defective neutrophil 74 
priming has been associated with recurrent infections (10). This delicate balance between 75 
augmented microbicidal function and increased risk of tissue injury is reflected by the 76 
complex signalling processes that regulate neutrophil priming. Herein we describe the 77 
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signals that establish priming and describe how neutrophils can de-prime, correlating in vitro 78 
observations with in vivo significance. 79 
 80 
Diversity of neutrophil priming in vitro and in vivo 81 
Primed neutrophils that are subsequently activated display enhanced phagocytosis, ROS 82 
generation, degranulation, release of bioactive mediators and NETosis (11). Numerous 83 
primer/activator combinations induce these changes, but the precise nature and duration of 84 
the primed phenotype varies; e.g. priming induced by PAF is transient, whilst growth factors 85 
such as GM-CSF establish a more durable primed state. Multiple molecular pathways 86 
including mitogen-activated protein kinases (p38 and ERK1/2) and phosphoinositide 3-87 
kinases (PI3Ks) are required for priming to occur; however subtle differences between 88 
priming agents are apparent even if convergence to common effector mechanisms occurs. 89 
For example, GM-CSF and TNF both promote p47phox phosphorylation to prime the 90 
respiratory burst, but rely on ERK and p38, respectively (12); RNAseq confirms that they 91 
activate both cytokine-specific and shared pathways (13). Identically primed neutrophils 92 
exposed to different activating agents also initiate diverse signals; TNF-primed neutrophils 93 
treated with either the bacterial tri-peptide fMLF or with bacteria display enhanced ROS 94 
production; both employ p38 signalling, but only fMLF also entrains ERK (14). Other 95 
activating agents such as C5a and LTB4 may also elicit different responses, but as most 96 
studies have used fMLF our review focuses on this agonist. 97 
 98 
Multiple priming influences co-exist in disease states in vivo. Different proportions of primed 99 
cells are seen to circulate in individual patients (15), perhaps related to differences in 100 
priming signal intensity, neutrophil maturation or the clearance of primed cells (16). 101 
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Likewise, cells isolated from pathological sites may display some, but not all of the hallmarks 102 
of priming (17). Because of this in vivo complexity, our understanding of priming and the 103 
signalling processes that underlie it comes mostly from in vitro studies with isolated human 104 
neutrophils exposed to single primer/activator combinations (e.g. TNF/fMLF; see Figure 2). 105 
However, neutrophil isolation itself may initiate partial priming and isolated cells are not 106 
subject to the modifying effects of other blood constituents on this process (18). Despite 107 
their limitations, in vitro approaches have provided valuable insights, with the potential to 108 
progress to settings recapitulating the complex in vivo environment, e.g. co-culture systems 109 
and animal models.  110 
 111 
Signalling priming responses in vivo and in vitro 112 
a). Reactive oxygen species production  113 
Generation of phagosomal ROS by the multi-component NADPH oxidase is vital for pathogen 114 
killing, whereas the secretion of extracellular ROS (which may be augmented dramatically by 115 
priming, see Figure 3) can cause major tissue injury both in vitro and in vivo (19, 20). 116 
Multiple molecular pathways and cellular events must be activated for priming of the 117 
respiratory burst to occur, with the timing and contribution of each step being context-118 
dependent. 119 
i). Oxidase assembly at the cell membrane  120 
The production of ROS is mediated by the flavocytochrome b558 (cytb558) oxidase, which is 121 
partly assembled at membranes following specific phosphorylation and cellular trafficking 122 
events upon priming. Components of the cytb558 oxidase gp91phox and p22phox are 123 
predominantly sited on granule membranes in resting cells, whilst p47phox, p67phox, p40phox 124 
and Rac2 are cytosolic. Priming mobilises cytb558-containing granules and vesicles to the 125 
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plasma membrane (14); in LPS-priming this was shown to increase expression of other 126 
relevant proteins such as fMLF receptors (FPR1) and CD11b (21), although this may not occur 127 
with all priming agents. The precise nature of the trafficking processes and their signalling 128 
controls are still debated and likely depend on the priming agent used. For example, LPS 129 
priming requires cytoskeletal changes and NADPH oxidase pre-assembly at Rab-5 positive 130 
endosomes (22, 23); subtly different findings were reported for PAF, which causes p40phox 131 
and p67phox, but not p47phox or gp91phox to re-locate to Rab5-positive endosomes (24; Figure 132 
3). However, the fundamental importance of granule trafficking to the priming process is 133 
shown by experiments blocking exocytosis either directly or indirectly (by the inhibition of 134 
clathrin-mediated endocytosis), which prevents priming of the respiratory burst by either 135 
TNF or PAF (25, 26).  The importance of the subtle differences between priming agents and 136 
the precise in vivo dependence of priming on endocytosis/exocytosis remain to be 137 
elucidated. 138 
ii). Phosphorylation of oxidase components 139 
In resting cells, p47phox is non-phosphorylated; on cellular activation it becomes highly 140 
phosphorylated (Figure 3) and undergoes conformational changes, facilitated by the proline 141 
isomerase Pin1 (reviewed in 27), unmasking multiple binding domains for interaction with 142 
other oxidase components and membrane phospholipids. Several priming agents induce 143 
p47phox phosphorylation at residue S345 via the JAK/STAT, p38 or ERK1/2 signalling cascades 144 
(12, 28, 29, 30), with the precise pathway depending on the priming agent. Subsequent 145 
exposure to activators leads to enhanced phosphorylation at further sites (11).  146 
The in vivo relevance of these events is demonstrated by neutrophils from patients with 147 
myeloproliferative disease due to a gain-of-function JAK2 mutation (V617F); such 148 
neutrophils exhibit constitutive S345 p47phox phosphorylation and are basally primed (32). A 149 
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similar phenotype has been observed in neutrophils from inflamed rheumatoid joints, where 150 
a competitive inhibitory S345-based peptide abolishes ROS production by these 151 
inflammatory cells, suggesting that this phosphorylation is critical for primed NADPH oxidase 152 
activity in vivo (12).   153 
NF-ʃ ƐŝŐŶĂůůŝŶŐ ĂůƐŽ ĐŽŶƚƌŝďƵƚĞƐ to p47phox phosphorylation in LPS-primed mouse 154 
neutrophils (28). Decreased neutrophil p47phox phosphorylation induced by LPS has been 155 
reported patients carrying mutations in NF-ʃ-modulating protein (IRAK4) (32). This resulted 156 
in reduced (NEMO-deficient cells) or absent (IRAK4-deficiency) LPS priming of the respiratory 157 
burst (33). Phosphorylation events involving other oxidase components are important for 158 
NADPH oxidase activation (26), but their relevance to priming is yet to be established.  159 
iii). Interactions with membrane phospholipids 160 
We have previously shown that PI3K-dependent PtdIns(3,4,5)P3 (PIP3) generation correlates 161 
with ROS release in vitro, and TNF-primed fMLF-stimulated human neutrophils display 162 
biphasic PI3K activation, with the second (PI3Kɷ isoform-dependent) phase governing 163 
primed ROS generation (33). The mechanism(s) by which PI3K regulates the primed 164 
respiratory burst appear context-dependent, but interactions with PI3K-generated 3-165 
phosphorylated lipids promote membrane translocation of oxidase components (reviewed 166 
in 34). Additionally, PI3K activates the Rac-GEF P-Rex1 and hence Rac, a critical NADPH 167 
oxidase-activating small GTPase; mouse neutrophils lacking P-Rex1 exhibit a defect in LPS- 168 
ROS formation (35). Interestingly, P-Rex1 has been identified as a potential anti-169 
inflammatory target in a mouse model of pulmonary fibrosis (36), although whether and 170 
how this relates to its impact on neutrophil priming is unclear. 171 
 172 
b). Priming of neutrophil degranulation  173 
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Neutrophil granules and secretory vesicles comprise a reservoir of antimicrobial products, 174 
NADPH oxidase components and receptors. Primary (azurophilic) granules incorporate 175 
histotoxic contents such as myeloperoxidase (MPO) and neutrophil elastase (NE). Secondary 176 
(specific) granules and tertiary (gelatinase) granules include adhesion molecules such as 177 
CD11b and FPR1. Secretory vesicles contain FPR1, CD11b and cytochrome b558.  Priming 178 
alone leads to exocytosis of secretory and gelatinase vesicles, with subsequent increased 179 
release of specific and azurophilic granule contents on exposure to activating agents (22, 180 
37). Several signalling pathways regulating primed ROS production also influence 181 
degranulation.  Cadwallader and colleagues (38) found that TNF-induced PI3K-dependent 182 
phospholipase D (PLD) activation is required for enhanced MPO and ROS secretion, and PLD 183 
activation likewise signals GM-CSF priming of NE release (39). Potera et al. (37) noted 184 
involvement of p38 and ERK1/2 in TNF-augmented granule release, but ROS suppressed the 185 
magnitude of this response, suggesting a negative feedback role.  Consistent with this, our 186 
group has shown that hypoxia sufficient to suppress NADPH oxidase function enhances 187 
primed (GM-CSF or PAF) neutrophil degranulation in a PI3Ky-dependent fashion (40).  188 
 189 
Primed granule exocytosis is tightly regulated and hierarchical; in an in vivo skin blister 190 
model, complete mobilisation of secretory vesicles was accompanied by discharge of 38% of 191 
tertiary, 22% of secondary and just 7% of primary granule proteins (41). A similar rank order 192 
of degranulation was observed in response to calcium ionophore, and calcium chelation 193 
abolishes secretion of all but secretory vesicles (42). Many priming agents induce calcium 194 
transients and enhance activation-induced calcium flux (39), influencing dynamic changes in 195 
the actin cytoskeleton required for granules mobilisation to the plasma membrane (43). 196 
Phospho-proteome analysis of primed neutrophils (22) supports the importance of 197 
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cytoskeletal reorganisation in priming for granule protein exocytosis. How these and other 198 
priming-relevant pathways might be manipulated in vivo is an important question. Of note, 199 
enhanced NE release associated with priming and tissue injury has been detected in several 200 
diseases (5, 44), and inhibition of neutrophil exocytosis was protective in rodent models of 201 
lung injury (45-47) demonstrating the in vivo relevance of this process and its potential value 202 
as a therapeutic target. 203 
 204 
c). Delayed apoptosis  205 
Most priming agents also delay the ability of neutrophils to undergo constitutive apoptosis, 206 
extending the time-frame over which these cells may combat infection or cause bystander 207 
injury. We and others have shown the effect of TNF to be biphasic, with an early increase in 208 
cell death followed by extended survival; TNF and other pro-survival priming agents such as 209 
GM-CSF induce changes in the expression, stability and function of an array of both pro- and 210 
anti-apoptotic proteins (48), with the balance between these pathways determining 211 
neutrophil lifespan (Figure 2). Thus, even when priming promotes survival, neutrophils 212 
encountering subsequent stimuli at the inflammatory site are also primed to die (e.g. 213 
through enhanced expression of Bim, 48).   214 
Priming agents such as GM-CSF delay apoptosis predominantly by increasing the stability of 215 
the anti-apoptotic protein Mcl-1, which normally has a very fast intracellular turnover time. 216 
Mcl-1 levels are down-regulated by proteasomal degradation and caspase activation but 217 
preserved by sustained activation of the PI3K effector Akt (49). Neutrophil Mcl-1 levels have 218 
been reported to be higher in neutrophils isolated from patients with COPD (50) and sepsis 219 
(51). In an animal model, attenuating Mcl-1 down-regulation inhibited neutrophil apoptosis 220 
and delayed the resolution of endotoxin-mediated lung inflammation (52), highlighting the 221 
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potential for manipulating these pathways in vivo. PI3K-dependent signalling also plays a 222 
role in the pro-survival effects of GM-CSF and TNF, in part via Akt-mediated phosphorylation 223 
of the pro-apoptotic Bcl-2 family member Bad (53). Neutrophils treated with PAF are 224 
dependent on both ERK1/2 and PI3K survival signals, with ERK- and PI3K-dependent Bad 225 
phosphorylation on residues S112 and S136, respectively (54).   226 
 227 
Understanding and elucidating these varied signalling pathways in the context of disease is 228 
important, since modulation of neutrophil activation status and apoptosis represents an 229 
emerging therapeutic strategy in chronic  ?ŐƌĂŶƵůŽĐǇƚĞ-dominated ? inflammatory disease 230 
(55).  231 
 232 
The interplay of priming and adhesion  233 
Most in vitro experiments are performed on neutrophils in suspension culture, stimulated 234 
with soluble agonists; whilst this may be relevant to circulating neutrophils exposed to 235 
priming agents in the bloodstream (Figure 1), adherent or post-migratory neutrophils display 236 
significantly altered functional properties. Priming agents impact greatly on the biophysical 237 
and adhesive properties of neutrophils and likewise the process of adhesion modifies 238 
neutrophil responses in a manner very akin to priming.   239 
Priming up-regulates the surface expression of neutrophil adhesion receptors such as CD11b 240 
(Figure 3) by mobilisation of secretory vesicles, both in vitro (56) and in vivo (57) and further 241 
increases the affinity (or avidity) of such integrins via  ?inside-out ? signalling. Engagement of 242 
integrins during ƚƌĂŶƐŵŝŐƌĂƚŝŽŶ ƐƚŝŵƵůĂƚĞƐ  ?ŽƵƚƐŝĚĞ-ŝŶ ? ƐŝŐŶĂůůŝŶŐ ? ǁŚŝĐŚ ƚŽŐĞƚŚĞƌ ǁŝƚŚ243 
exposure to endothelial-bound mediators such as PAF ensures that neutrophils are primed 244 
as they egress (58; see Figure 1). The engagement of such receptors can alter neutrophil 245 
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responsiveness dramatically; for example cells adherent to fibronectin release substantial 246 
ROS on exposure to TNF (normally regarded as a priming agent rather than an activating 247 
stimulus) (59) and display sequential PI3K and ɷ-PKC activation, with ɷ-PKC-dependent 248 
phosphorylation of p47phox (60). Of note, these effects are agonist-specific, as treatment of 249 
adherent cells with fMLF resulted in ɷ-PKC-independent ROS generation (58). Reminiscent of 250 
the biphasic PI3K activation seen in neutrophils primed in suspension (33), stimulation of 251 
adherent mouse neutrophils induced a biphasic NADPH oxidase response, the initial phase 252 
being ƐŝŐŶĂůůĞĚ ďǇ W/ ?<ɶ ? ǁŝƚŚ Ă ƌŽůĞ ĨŽƌ W/ ?<ɲ ?ɷ ŝŶ ƚŚĞ ƐƵď ĞƋƵĞŶƚ ƉƌŽůŽŶŐĞĚ ƉŚĂƐĞ; src-253 
family kinases were critical for both phases in this setting (62). 254 
 255 
Neutrophil L-selectin (CD62L) mediates initial rolling interactions with the endothelium, and 256 
its rapid, often near-total shedding provides a sensitive marker of neutrophil priming both in 257 
vitro (56) and in vitro (57). Circulating neutrophils in mice expressing an L-selectin point 258 
mutation (N138G), which modifies force-catch bonds induced by mechano-stimulation, form 259 
unstable aggregates and are primed in vivo (62); this priming status is associated with 260 
enhanced bacterial clearance, but increases inflammatory injury and enlarged venous 261 
thrombi, again emphasising the precarious tightrope between host defence and tissue 262 
injury. These primed neutrophils do not adhere via ɴ ?-integrin differently from control 263 
neutrophils, suggesting an alternative form of priming by mechano-transduction (63). 264 
 265 
De-priming 266 
It was initially assumed that neutrophil priming was an irreversible process. However, proof 267 
of concept experiments with PAF demonstrated the potential for near complete recovery 268 
back to a quiescent or de-primed state. With PAF this was shown to be a spontaneous event, 269 
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with a re-setting of fMLF-triggered NADPH oxidase response and near-complete recovery 270 
from a polarised to a rounded morphology (7). Our group has recently shown the potential 271 
for this process to occur in vivo in humans, with immediate (first pass) trapping of injected 272 
exogenously (GM-CSF)-primed neutrophils within the very narrow pulmonary capillaries, 273 
followed by their subsequent gradual release back into the systemic circulation, a finding 274 
that we propose to reflect in situ de-priming (8).  Furthermore, the ability of repeated 275 
mechanical deformation of neutrophils (achieved by optical lasers or by passage through a 276 
series of multiple 5-µm micro-channels) highlights the mechano-sensitive nature of 277 
neutrophils and the potential for active and rapid de-priming of these cells (57). This 278 
recovery option for primed neutrophils fits with mathematical modelling of the number of 279 
circulating primed neutrophils found in disease settings (64) and may play a role in the now 280 
well-recognised capacity of murine neutrophils to return from sites of inflammation back to 281 
the systemic circulation (retro-transmigration) (65) or to the bone marrow and lymph node 282 
(66). Mechanistically however, very little is known about the effects of de-priming on cell 283 
signalling events or the restoration of neutrophil cell surface receptors and molecules 284 
involved in adhesion and other immune functions. Likewise, whether the de-primed 285 
neutrophil is entirely indistinguishable from the un-primed neutrophil and the true 286 
physiological role and fate of these cells also needs to be determined. 287 
 288 
In summary, priming appears to be one of the key processes designed to regulate neutrophil 289 
function, with the capacity to either restrain (un-primed/basal state) or greatly enhance 290 
(primed state) their repertoire of functional responses: this process therefore acts as a 291 
 ?ǀŽůƵŵĞ ƐǁŝƚĐŚ ? ĨŽƌ ƚŚĞ ĨƵŶĐƚŝŽŶĂl reactivity of these cells to any activating agonist they 292 
subsequently encounter. As part of the priming process, this causes a dramatic change in cell 293 
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contour and deformability, and re-programmes the susceptibility of these cells to undergo 294 
apoptotic cell death. Understanding the signalling processes involved in priming and de-295 
priming should allow therapeutic opportunity to limit granulocyte-mediated tissue damage.  296 
 297 
  298 
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Figure Legends 299 
 300 
 301 
Figure 1: Neutrophil priming and de-priming in vivo: potential sites and consequences 302 
Circulating quiescent neutrophils (1) may encounter intravascular priming agents (2) with 303 
the potential for local damage (3); if sequestered in the pulmonary capillary bed neutrophils 304 
have the potential to gradually de-prime and be released back in to the systemic circulation 305 
(4). Circulating neutrophils may become primed on egressing the circulation both by 306 
engagement of adhesion receptors and by encountering endothelial-bound or tissue-307 
associated priming agents (5). Primed neutrophils ingest and kill bacteria, with the risk of 308 
collateral ƚŝƐƐƵĞĚĂŵĂŐĞ ? ? ? ?WƌŝŵĞĚŶĞƵƚƌŽƉŚŝůƐĂƌĞĂůƐŽ ?ƉƌŝŵĞĚƚŽĚŝĞ ?ŝŶƌĞƐƉŽŶƐĞƚŽĐƵĞƐ309 
at the inflammatory site (7) or may de-prime spontaneously (8). 310 
 311 
 312 
Figure 2: Signalling events underlying TNF priming of fMLF-mediated neutrophil activation 313 
Priming with TNF activates multiple signalling pathways, including p38 and ERK1/2, PI3K and 314 
NF-ʃB, with both linear and overlapping downstream consequences. TNF-mediated 315 
phosphorylation of p47phox is largely dependent on p38, whilst both ERK1/2 and p38 mobilise 316 
secretory vesicles to the cell surface. Both of these actions promote and enhanced the 317 
respiratory burst on subsequent exposure to an activating agent such as fMLF. 318 
Simultaneously, multiple pathways influence the balance of pro- and anti-apoptotic proteins 319 
such as Bad and Mcl1. On exposure to fMLF, enhanced PI3K activation acts on the primed 320 
cell to enhance assembly and activation of the multi-component NADPH oxidase. PI3K-321 
stimulated PLD activation, together with calcium transients and changes in the cytoskeletal 322 
architecture, promote enhanced degranulation.  323 
 324 
 325 
Figure 3: Cellular and molecular events involved in neutrophil priming 326 
Circulating or unstimulated neutrophils are largely spherical and express a limited number of 327 
receptors on their surface; p47phox, a cytosolic component of the NADPH oxidase, is present 328 
in the cytosol in a non-phosphorylated state. Priming induces neutrophil shape change with 329 
polarisation, and secretory vesicle exocytosis increases the expression of NADPH oxidase 330 
subunits gp91phox and p22phox, as well as other molecules such as integrins and FPR1. p47phox 331 
becomes partially phosphorylated, and following interaction with Pin1, undergoes a 332 
conformational change facilitating interactions with membrane phospholipids and other 333 
oxidase components. NADPH oxidase components such as p67phox and p40phox are recruited 334 
to Rab5/EEA1 positive endosomes in preparation for delivery to the plasma membrane. 335 
Subsequent activation of the primed neutrophil enables a fully functional NADPH oxidase 336 
complex to become assembled and activated, associated with enhanced granule protein 337 
exocytosis.   338 
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List of Abbreviation 611 
PAF  Platelet-activating factor 612 
GM-CSF Granulocyte macrophage  ? colony stimulating factor 613 
fMLF  formyl-methionyl-leucyl-phenylalanine 614 
TNF  Tumour necrosis factor 615 
PI3K  PhosphoInositide 3-kinase 616 
cytb558  flavocytochrome b558  617 
C5a  Complement factor 5a 618 
ROS  Reactive oxygen species 619 
NADPH Nicotinamide adenine dinucleotide phosphate 620 
ERK  Extracellular regulated kinase 621 
LPS  Lipopolysaccharide 622 
JAK/STAT Janus kinase/Signal transducers and activators of transcription 623 
NF-ʃB  Nuclear factor kappa-light-chain-enhancer of activated B cells 624 
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IRAK  Interleukin-1 receptor-associated kinase 1 625 
NEMO  NF-ʃB essential modulator 626 
PIP3  Phosphatidylinositol (3,4,5)-trisphosphate 627 
MPO  Myeloperoxidase 628 
PLD  Phospholipase D 629 
NE  Neutrophil elastase 630 
AKT  Protein kinase B 631 
PKC  Protein kinase C 632 
FPR1  Formyl peptide receptor 1 633 
